Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Conjugated fatty acids drive ferroptosis through chaperone-mediated autophagic degradation of GPX4 by targeting mitochondria.
Hirata Y, Yamada Y, Taguchi S, Kojima R, Masumoto H, Kimura S, Niijima T, Toyama T, Kise R, Sato E, Uchida Y, Ito J, Nakagawa K, Taguchi T, Inoue A, Saito Y, Noguchi T, Matsuzawa A. Hirata Y, et al. Among authors: niijima t. Cell Death Dis. 2024 Dec 6;15(12):884. doi: 10.1038/s41419-024-07237-w. Cell Death Dis. 2024. PMID: 39643606 Free PMC article.
Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.
Kuroda M, Niijima T, Kotake T, Akaza H, Hinotsu S; 6th Trial of the Japanese Urological Cancer Research Group. Kuroda M, et al. Among authors: niijima t. Eur Urol. 2004 May;45(5):600-5. doi: 10.1016/j.eururo.2003.12.010. Eur Urol. 2004. PMID: 15082202 Clinical Trial.
[Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin].
Hinotsu S, Akaza H, Isaka S, Kagawa S, Koiso K, Kotake T, Machida T, Matsumura Y, Niijima T, Obata K, Ohashi Y, Ohe H, Shimazaki J, Tashiro K; Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin. Hinotsu S, et al. Among authors: niijima t. Gan To Kagaku Ryoho. 2002 Jan;29(1):73-80. Gan To Kagaku Ryoho. 2002. PMID: 11816482 Clinical Trial. Japanese.
Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin.
Obata K, Ohashi Y, Akaza H, Isaka S, Kagawa S, Koiso K, Kotake T, Machida T, Matsumura Y, Niijima T, et al. Obata K, et al. Among authors: niijima t. Cancer Chemother Pharmacol. 1994;35 Suppl:S88-92. doi: 10.1007/BF00686928. Cancer Chemother Pharmacol. 1994. PMID: 7994795 Clinical Trial.
[Combination therapy with natural type human tumor necrosis factor (MHR-24) and human lymphoblastoid interferon-alpha (MOR-22) against renal cell carcinoma--a multiclinic cooperative, early phase II study. Subcommittee on Urogenital Malignancy, Committee on MHR-24 against Tumors].
Niijima T, Akaza H, Koyanagi T, Togashi M, Kumamoto Y, Funyu T, Suzuki T, Orikasa S, Yoshikawa K, Koiso K, et al. Niijima T, et al. Hinyokika Kiyo. 1992 Oct;38(10):1201-7. Hinyokika Kiyo. 1992. PMID: 1481783 Free article. Clinical Trial. Japanese.
[Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Bladder cancer BCG Study Group].
Akaza H, Kameyama S, Kakizoe T, Kojima H, Koiso K, Aso Y, Niijima T. Akaza H, et al. Among authors: niijima t. Nihon Hinyokika Gakkai Zasshi. 1992 Feb;83(2):183-9. doi: 10.5980/jpnjurol1989.83.183. Nihon Hinyokika Gakkai Zasshi. 1992. PMID: 1556836 Free article. Clinical Trial. Japanese.
Evaluation of systemic chemotherapy with methotrexate, vinblastine, adriamycin, and cisplatin for advanced bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin.
Kotake T, Akaza H, Isaka S, Kagawa S, Koiso K, Machida T, Maru A, Matsumura Y, Miyagawa I, Niijima T, et al. Kotake T, et al. Among authors: niijima t. Cancer Chemother Pharmacol. 1992;30 Suppl:S85-9. doi: 10.1007/BF00686950. Cancer Chemother Pharmacol. 1992. PMID: 1394826 Clinical Trial.
208 results